Association of primary prophylactic (PP) granulocyte-colony stimulating factor (G-CSF) use with chemotherapy dose modifications and relative dose intensity (RDI) among breast cancer patients receiving high-risk regimens for febrile neutropenia (FN).

Jaime Shaw,Jennifer Schenfeld,Akhila Balasubramanian,Renee R Jaramillo,Darcie Sandschafer,Michael A. Kelsh,Reshma Mahtani

Association of primary prophylactic (PP) granulocyte-colony stimulating factor (G-CSF) use with chemotherapy dose modifications and relative dose intensity (RDI) among breast cancer patients receiving high-risk regimens for febrile neutropenia (FN).

2021

Jaime Shaw
Jennifer Schenfeld
Akhila Balasubramanian
Renee R Jaramillo
Darcie Sandschafer
Michael A. Kelsh
Reshma Mahtani

314Background: FN is a primary driver of chemotherapy modification and reduced RDI. Breast cancer patients often receive regimens with high risk ( > 20%) for FN. PP G-CSF use is recommended to decr...

Keywords:

Oncology
dose intensity
Febrile neutropenia
Chemotherapy
Breast cancer
Granulocyte colony-stimulating factor
Medicine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations